MacroGenics’ (NASDAQ:MGNX) margetuximab received FDA orphan drug designation for the treatment of gastric and gastroesophageal junction cancer.
Margetuximab is currently being evaluated in a Phase 2/3 trial in combination with checkpoint inhibition, with or without chemotherapy, as a potential first-line treatment for patients with HER2-positive gastric or gastroesophageal junction cancer.
“We believe that our immune-enhancing antibody targeting HER2 has the potential to improve upon the clinical activity of existing standard of care for patients with gastric or gastroesophageal cancer,” Dr. Scott Koenig, MacroGenics’ president and CEO, said in a statement.
